Sep 30, 2019

Blueprint Medicines Q3 2019 Earnings Report

Total Revenue
$9.14M
Previous year: $1.1M
+734.6%
EPS
-$1.93
Previous year: -$1.66
+16.3%
R&D Expenses
$81.5M
SG&A Expenses
$25.6M
Gross Profit
-$72.3M
Cash and Equivalents
$89.2M
Free Cash Flow
-$77.9M
Total Assets
$738M

Blueprint Medicines

Blueprint Medicines